Mandating the human papillomavirus
If a woman is found to be pregnant during the three-dose series of vaccination, the series will be postponed until pregnancy has been completed.
While there is no indication for intervention for vaccine dosages administered during pregnancy, patients and health-care providers are encouraged to report exposure to vaccines to the appropriate HPV vaccine pregnancy registry.
Neither vaccine prevents other sexually transmitted diseases, nor do they treat existing HPV infection or cervical cancer.
A study with 9v HPV, a 9-valent HPV vaccine that protects against HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58, came to the result that the rate of high-grade cervical, vulvar, or vaginal disease was the same as when using a quadrivalent HPV vaccine.
In 2018, the Food and Drug Administration released a summary basis for regulatory action and approval for expansion of usage and indication for the 9 valent HPV vaccine to include men and women 27 to 45 years of age.
The National Cancer Institute states "Widespread vaccination has the potential to reduce cervical cancer deaths around the world by as much as two-thirds if all women were to take the vaccine and if protection turns out to be long-term.
Overall, about 30 percent of cervical cancers will not be prevented by these vaccines.
Also, in the case of Gardasil, 10 percent of genital warts will not be prevented by the vaccine.
In the Gardasil clinical trials, 1,115 pregnant women received the HPV vaccine.
Vaccination before adolescence, therefore, makes it more likely that the recipient has not been exposed to HPV.
Since penile and anal cancers are much less common than cervical cancer, HPV vaccination of young men is likely to be much less cost-effective than for young women.
A lack of a difference may have been caused by the study design of including women 16 to 26 years of age, who may largely already have been infected with the five additional HPV types that are additionally covered by the 9-valent vaccine.
HPV vaccines are approved for males in several countries, including Canada, Australia, Ireland, South Korea, Hong Kong, the United Kingdom, New Zealand, and the United States.